Please Wait.....
Report
Ovarian Cancer Pipeline Analysis Report
Market Report I 2024-08-29 I 150 Pages I EMR Inc.
Ovarian Cancer Drug Pipeline Analysis 2024
The drug pipeline is significantly driven by the increasing prevalence of ovarian cancer, affecting more than 324,603 women worldwide annually. In the United States, about 19,710 new cases are expected to be diagnosed in 2024, with an estimated 238,484 women currently living with the disease, making it a major health concern globally.
Key Takeaways
- Major companies involved in the ovarian cancer drug pipeline market include Sanofi, AstraZeneca, Seagen Inc., Bristol-Myers Squibb, and GlaxoSmithKline.
- The current drug pipeline for ovarian cancer includes promising candidates such as niraparib, olaparib, rucaparib, and bevacizumab, among others.
- Regulatory agencies are providing support through expedited pathways for drug approvals and designations, encouraging rapid development and market availability of new therapies.
Report Coverage
The ovarian cancer drug pipeline analysis provides an overview of recent advancements and ongoing clinical trials. The report highlights progress in targeted therapies and immunotherapies, aiming for improved survival rates and quality of life. It covers innovative approaches such as PARP inhibitors, which target DNA repair pathways, and angiogenesis inhibitors which restrict tumor blood supply. The competitive landscape examines collaborations and strategic partnerships that accelerate R&D. It also discusses regulatory milestones achieved by investigational drugs, highlighting their impact on future treatment paradigms, and promising more effective and personalized treatment options for ovarian cancer patients.
Ovarian Cancer Drug Pipeline Outlook
Ovarian cancer, a serious condition affecting thousands globally, is characterized by the growth of malignant cells in the ovaries. It often goes undetected until it has spread within the pelvis and abdomen, making it more challenging to treat. Subtypes of ovarian cancer, such as epithelial ovarian carcinomas, account for most cases and require diverse treatment strategies.
In 2024, significant advancements in ovarian cancer treatment have been made. The FDA approved Elahere (mirvetuximab soravtansine-gynx) for patients with folate receptor alpha (FR?) positive, platinum-resistant ovarian cancer, providing a new treatment option that has demonstrated improved progression-free survival in clinical trials.
Significant advancements in treatment have been made in recent years, particularly with the development of PARP inhibitors like niraparib and olaparib, which offer new options for patients with BRCA mutations. The market is witnessing increased investment in research and development and regulatory approvals for innovative drugs, underscoring a dynamic landscape focused on enhancing patient outcomes.
Ovarian Cancer- Pipeline Drug Profiles
Recent developments in ovarian cancer treatment have introduced several promising drugs currently in clinical trials:
- Docetaxel and Cisplatin: These are cornerstone chemotherapeutic agents used in combination regimens for ovarian cancer. Docetaxel is a taxane that disrupts microtubule function, while cisplatin forms DNA crosslinks, leading to apoptosis. Their combination enhances cytotoxicity against resistant ovarian cancer cells.
- Liposomal Doxorubicin: This formulation of doxorubicin encapsulates the drug in liposomes, enhancing delivery to tumor tissues and reducing systemic toxicity. It is particularly effective against recurrent ovarian cancer, offering a favorable safety profile compared to traditional doxorubicin.
- Paclitaxel: A microtubule inhibitor that stabilizes tubulin polymerization, paclitaxel is used in combination with platinum-based drugs for first-line treatment. It has a critical role in both primary and maintenance therapy settings.
- Olaparib, MEDI4736, Bevacizumab: Olaparib is a PARP inhibitor for BRCA-mutated ovarian cancer, while MEDI4736 (durvalumab) is an immune checkpoint inhibitor targeting PD-L1, and bevacizumab is an anti-angiogenic agent. This combination leverages multiple mechanisms to enhance therapeutic efficacy.
Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Ovarian Cancer drugs based on various segmentations such as:
Analysis by Route of Administration
- Oral
Oral administration is commonly used for PARP inhibitors such as niraparib (Zejula) and olaparib (Lynparza). These drugs offer convenience and improve patient adherence to treatment regimens, as they can be taken at home rather than requiring a visit to a healthcare facility. Olaparib specifically targets DNA repair pathways and is pivotal in maintenance therapy for patients with BRCA mutations, helping to prolong progression-free survival and improve outcomes.
- Parenteral
Parenteral administration involves delivering drugs intravenously, ensuring rapid delivery and absorption, especially in aggressive cancer types. Bevacizumab (Avastin) is a prime example, administered intravenously to inhibit angiogenesis. By blocking the formation of new blood vessels that tumors need to grow, bevacizumab enhances progression-free survival when used in combination with chemotherapy.
- Others
Emerging delivery methods such as intraperitoneal chemotherapy are being explored to directly target tumor cells within the abdominal cavity. Intraperitoneal cisplatin is a notable example, allowing high local drug concentrations with reduced systemic toxicity compared to systemic chemotherapy. This method provides direct contact with cancer cells, enhancing therapeutic efficacy and minimizing side effects.
Analysis by Phase
According to EMR analysis, Phase II clinical trials dominate the ovarian cancer drug pipeline. The number of ovarian cancer drugs currently in Phase 2 clinical trials varies as new trials are continually initiated and completed. However, as of the latest data, there are over 58 ongoing Phase 2 trials for ovarian cancer drugs worldwide. These trials involve a wide range of therapeutic approaches, including targeted therapies, immunotherapies, and combination treatments.
- Preclinical Phase: Laboratory and animal studies to assess safety and efficacy.
- Phase I: Small-scale human trials focusing on safety and dosage.
- Phase II: Larger trials to evaluate efficacy and side effects.
- Phase III: Large-scale trials to confirm effectiveness, monitor side effects, and compare with standard treatments.
- Phase IV: Post-marketing studies to gather more information on risks, benefits, and optimal use.
Analysis by Drug Class
- Monoclonal Antibody
Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance, or mimic the immune system's attack on cancer cells. Bevacizumab (Avastin) targets the vascular endothelial growth factor (VEGF), inhibiting angiogenesis, the process of new blood vessel formation that tumors need to grow. Bevacizumab is pivotal in combination therapies for ovarian cancer, as it restricts the tumor's blood supply, helping to slow the progression of the disease.
- Recombinant Fusion Proteins
Recombinant fusion proteins are engineered to combine functional domains from different proteins, enhancing therapeutic effects. Aflibercept is a fusion protein that acts as a decoy receptor for VEGF, thereby inhibiting blood vessel growth within tumors. This approach helps to cut off the blood supply to the tumor, aiming to starve it and limit its ability to grow and spread.
- Small Molecule
Small molecules are low-molecular-weight compounds that can penetrate cells easily and disrupt intracellular processes. Olaparib (Lynparza) is a PARP inhibitor that interferes with DNA repair processes in cancer cells, making it particularly effective in treating BRCA-mutated ovarian cancer. By blocking PARP, olaparib induces cell death in cancer cells, which rely on this pathway for survival.
- Gene Therapy
Gene therapy involves delivering genetic material into cells to correct or alter defective genes responsible for disease development. Although still in the experimental stages for ovarian cancer, gene therapy aims to target oncogenes or restore tumor suppressor genes to inhibit cancer growth and progression. This approach holds the potential for personalized and curative treatments.
- Peptide
Peptide-based therapies utilize short chains of amino acids to interfere with specific biological pathways involved in cancer progression. Cilengitide is a peptide that targets integrins, which are proteins involved in cell adhesion and metastasis. By disrupting these interactions, cilengitide may inhibit cancer cell spread and metastasis, making it a promising candidate for further research.
- Polymer
Polymeric drug delivery systems are designed to improve the solubility, stability, and bioavailability of therapeutic agents. For example, liposomal doxorubicin encapsulates doxorubicin in liposomes, enhancing drug delivery to tumor sites while reducing systemic toxicity. This formulation improves the therapeutic index of the drug, making it more effective and safer for patients.
Ovarian Cancer Drug Clinical Trials Assessment- Competitive Dynamics
Here are a few notable participants involved in Ovarian Cancer research and development:
These advancements represent significant steps forward in Ovarian Cancer treatment, potentially offering patients more effective and less burdensome options.
Sanofi
Sanofi, headquartered in Paris, France, is dedicated to developing targeted therapies for ovarian cancer. Their pipeline includes immunotherapies that aim to enhance the body's immune response against tumor cells. One of their notable drugs is SAR439859, an oral selective estrogen receptor degrader (SERD) that targets estrogen receptors in cancer cells, providing a potential treatment option for hormone-driven ovarian cancers.
AstraZeneca
AstraZeneca, headquartered in Cambridge, UK, is a leader in developing PARP inhibitors for ovarian cancer, with olaparib (Lynparza) being one of their most prominent therapies. Olaparib targets DNA repair mechanisms in cancer cells, particularly effective in BRCA-mutated ovarian cancer, and is part of a personalized treatment approach that improves patient outcomes by exploiting cancer cell vulnerabilities.
Seagen Inc.
Seagen Inc., based in Bothell, Washington, specializes in antibody-drug conjugates (ADCs) for cancer treatment. Their innovative delivery systems aim to increase drug efficacy while minimizing systemic toxicity. Tisotumab vedotin is an ADC developed by Seagen for the treatment of recurrent or metastatic ovarian cancer, designed to deliver cytotoxic agents directly to cancer cells.
Bristol-Myers Squibb
Bristol-Myers Squibb, headquartered in New York City, is advancing immunotherapies like nivolumab (Opdivo), which enhance anti-tumor immune responses by blocking immune checkpoint pathways. This approach helps to reinvigorate T-cells, allowing them to effectively target and destroy ovarian cancer cells. Their research aims to integrate immune checkpoint blockade with standard care, improving outcomes for ovarian cancer patients.
Other key players in the market include GlaxoSmithKline, Lipomedix Pharmaceuticals Inc., Astellas Pharma Inc., Genentech, Inc., and Bayer AG.
Reasons To Purchase This Report
The Ovarian Cancer drug pipeline analysis report offers invaluable insights into the latest advancements and future trends in Ovarian Cancer treatment. It provides detailed evaluations of emerging therapies, pipeline assessment, and competitive landscape analysis, enabling informed investment decisions and strategic planning.
Key Questions Answered in the Ovarian Cancer Drug Pipeline Analysis Report
- What is the current state of the ovarian cancer drug pipeline?
- How many companies are currently involved in ovarian cancer drug development?
- What is the number of drugs in Phase III and Phase IV trials for ovarian cancer?
- Which organisations are at the forefront of ovarian cancer drug research?
- What are the effectiveness and safety profiles of the drugs in the ovarian cancer pipeline?
- What opportunities and challenges exist in the ovarian cancer clinical trial landscape?
- Which companies are leading the major clinical trials for ovarian cancer drugs?
- Which regions are involved in clinical trials for ovarian cancer?
- What are the recent clinical trial results for ovarian cancer drugs?
- What are the emerging trends in ovarian cancer clinical trials?
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Ovarian Cancer
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Ovarian Cancer
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Ovarian Cancer: Epidemiology Snapshot
5.1 Ovarian Cancer Incidence by Key Markets
5.2 Ovarian Cancer- Patients Seeking Treatment in Key Markets
6 Ovarian Cancer: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Ovarian Cancer: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Ovarian Cancer, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Ovarian Cancer Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Ovarian Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Olaparib
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Caelyx
10.2.3 Pegylated Liposomal Doxorubicin hydrochloride
10.2.4 Niraparib
10.2.5 Other Drug
11 Ovarian Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Bevacizumab
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 DCVAC/OvCa
11.2.3 Aflibercept
11.2.4 Dostarlimab
11.2.5 Other Drugs
12 Ovarian Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Carboplatin
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 GRN-300
12.2.3 Pazopanib
12.2.4 Pazopanib
12.2.5 Other Drugs
13 Ovarian Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 SZ011 CAR-NK
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Anti-Mesothelin Car NK Cells
13.2.3 Anti-MESO CAR-T cells
13.2.4 Pembrolizumab
13.2.5 Other Drugs
14 Ovarian Cancer, Key Drug Pipeline Companies
14.1 Sanofi
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 AstraZeneca
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Seagen Inc.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Bristol-Myers Squibb
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 GlaxoSmithKline
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Lipomedix Pharmaceuticals Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Astellas Pharma Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
14.8 Genentech, Inc.
14.8.1 Company Snapshot
14.8.2 Pipeline Product Portfolio
14.8.3 Financial Analysis
14.8.4 Recent News and Developments
14.9 Bayer AG
14.9.1 Company Snapshot
14.9.2 Pipeline Product Portfolio
14.9.3 Financial Analysis
14.9.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security